Prevalence and outcome of chronic hepatitis C patients admitted with COVID-19 to intensive care units: a blessing in disguise
Background Managing COVID-19 pneumonia is, in reality, one of the biggest challenges in the history of intensive care medicine. The link between comorbidity and COVID-19 remains unclear. Worldwide, Egypt has the highest prevalence of hepatitis C virus (HCV). The study’s objectives were to assess the prevalence of chronic hepatitis C as a risk factor among COVID-19 patients and to investigate the impact of it and the prior exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 patients. Results Of 2106 confirmed cases of COVID-19, CLD, malignancy, and chronic kidney disease were significant risk factors for death [OR (95% CI) = 2.78 (1.29–5.98), 2.72 (1.14–6.46) and 3.79 (1.39–10.36) respectively]. The mortality rate was 24.3%. A total of 99 cases (4.7%) with CLD were investigated during the study period; 69 patients (3.3%) were categorized as HCV-positive. Among the positive HCV cases, 49 patients (2.3%) received anti-hepatitis C medications. The mortality rate was 46.4% and 73.3% between HCV and non-HCV hepatic patients, respectively. Triple therapy showed a statistically significant association with a better outcome (p value = 0.009). Conclusions In the present report, chronic liver diseases, chronic kidney disease, and malignancy were significant risk factors for mortality among COVID-19 patients. The Egyptian mass management of chronic hepatitis C may explain the favorable outcome of COVID-19 among these patients. Intervention trials are required to prove that direct-acting antivirals are effective in preventing COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Ain-Shams journal of anaesthesiology - 15(2023), 1 vom: 16. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Negm, Essamedin M. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s42077-023-00396-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053770471 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053770471 | ||
| 003 | DE-627 | ||
| 005 | 20231117064826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231117s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s42077-023-00396-6 |2 doi | |
| 035 | |a (DE-627)SPR053770471 | ||
| 035 | |a (SPR)s42077-023-00396-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Negm, Essamedin M. |e verfasserin |0 (orcid)0000-0003-3303-6870 |4 aut | |
| 245 | 1 | 0 | |a Prevalence and outcome of chronic hepatitis C patients admitted with COVID-19 to intensive care units: a blessing in disguise |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Managing COVID-19 pneumonia is, in reality, one of the biggest challenges in the history of intensive care medicine. The link between comorbidity and COVID-19 remains unclear. Worldwide, Egypt has the highest prevalence of hepatitis C virus (HCV). The study’s objectives were to assess the prevalence of chronic hepatitis C as a risk factor among COVID-19 patients and to investigate the impact of it and the prior exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 patients. Results Of 2106 confirmed cases of COVID-19, CLD, malignancy, and chronic kidney disease were significant risk factors for death [OR (95% CI) = 2.78 (1.29–5.98), 2.72 (1.14–6.46) and 3.79 (1.39–10.36) respectively]. The mortality rate was 24.3%. A total of 99 cases (4.7%) with CLD were investigated during the study period; 69 patients (3.3%) were categorized as HCV-positive. Among the positive HCV cases, 49 patients (2.3%) received anti-hepatitis C medications. The mortality rate was 46.4% and 73.3% between HCV and non-HCV hepatic patients, respectively. Triple therapy showed a statistically significant association with a better outcome (p value = 0.009). Conclusions In the present report, chronic liver diseases, chronic kidney disease, and malignancy were significant risk factors for mortality among COVID-19 patients. The Egyptian mass management of chronic hepatitis C may explain the favorable outcome of COVID-19 among these patients. Intervention trials are required to prove that direct-acting antivirals are effective in preventing COVID-19. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Comorbidities |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CLD |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatitis C |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a DAAs |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a El-Sokkary, Rehab H. |4 aut | |
| 700 | 1 | |a Malek, Mai M. |4 aut | |
| 700 | 1 | |a Ezzat, Heba M. |4 aut | |
| 700 | 1 | |a Tawfik, Ahmed E. |4 aut | |
| 700 | 1 | |a Abed, Heba Ali |4 aut | |
| 700 | 1 | |a ELdeeb, Seham Mahmoud |4 aut | |
| 700 | 1 | |a Mohamed, Mohamed Sorour |4 aut | |
| 700 | 1 | |a Kassem, Hamdy M. |4 aut | |
| 700 | 1 | |a Mosallem, Ahmed |4 aut | |
| 700 | 1 | |a Mowafy, Sherif M. S. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ain-Shams journal of anaesthesiology |d [Berlin : Springer Berlin Heidelberg, 2007 |g 15(2023), 1 vom: 16. Nov. |w (DE-627)SPR038415356 |w (DE-600)2732723-1 |x 2090-925X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:16 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s42077-023-00396-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 16 |c 11 | ||